Marshall Wace LLP Increases Stock Holdings in Fresenius Medical Care AG (NYSE:FMS)

Marshall Wace LLP lifted its position in Fresenius Medical Care AG (NYSE:FMS) by 8.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,363 shares of the company’s stock after purchasing an additional 1,207 shares during the quarter. Marshall Wace LLP’s holdings in Fresenius Medical Care were worth $293,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC boosted its stake in Fresenius Medical Care by 21.8% during the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock worth $82,000 after buying an additional 758 shares during the period. Wulff Hansen & CO. lifted its position in shares of Fresenius Medical Care by 1,809.0% during the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after purchasing an additional 325,439 shares in the last quarter. QRG Capital Management Inc. lifted its position in shares of Fresenius Medical Care by 19.5% during the first quarter. QRG Capital Management Inc. now owns 54,363 shares of the company’s stock worth $1,048,000 after purchasing an additional 8,870 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Fresenius Medical Care by 50.0% during the first quarter. SG Americas Securities LLC now owns 15,228 shares of the company’s stock worth $294,000 after purchasing an additional 5,078 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC acquired a new stake in shares of Fresenius Medical Care during the first quarter worth about $584,000. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Stock Down 1.4 %

FMS stock opened at $19.60 on Friday. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. Fresenius Medical Care AG has a twelve month low of $16.37 and a twelve month high of $22.76. The company’s 50 day moving average is $19.82 and its two-hundred day moving average is $20.03. The stock has a market cap of $11.50 billion, a P/E ratio of 20.25, a PEG ratio of 1.06 and a beta of 0.91.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.38. The company had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. Research analysts expect that Fresenius Medical Care AG will post 1.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

FMS has been the topic of several analyst reports. StockNews.com initiated coverage on shares of Fresenius Medical Care in a report on Tuesday. They issued a “strong-buy” rating on the stock. Truist Financial raised their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $23.00.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.